Evaluation of colposcopy results for patients who are HPV DNA positive in KETEM

Abstract

We evaluated colposcopy and postoperative biopsy results in cases referred to our oncology center from the Cancer Early Diagnosis and Treatment Center (KETEM) due to Human Papilloma Virus (HPV) positivity and/or cervical premalignant lesion (CPL). A total of 1230 female patients who were admitted to Oncology outpatient clinic between January 2016 and December 2017 with positive HPV DNA screening tests from KETEM regardless of whether they had cervical premalignant lesion or not as a result of Papanicolaou smear (PAP smear) were included in the study. Colposcopy was performed in all cases and cervical biopsy was performed in patients who had suspicious lesions. No significant relationship was found between smoking status, educational status and financial status and HPV DNA screening test results (p = 0.123, p = 0.201, p = 0.244, respectively). The sensitivity of colposcopy to detect cervical premalignant lesions was 99.2% and positive predictive value (PPD) was 74.1%. In determining the cervical premalignant lesions, the sensitivity of smear was 41.3% and its specificity was 66.5%, PPV (positive predictive value) was 78.1% and NPV (negative predictive value) was 28.2%. In our study, the sensitivity of the HPV test to determine cervical premalignant lesions was 93.1%, PPV was 74%, specificity 86% and NPV was 30%. The accuracy of HPV types in determining CPLs was found to be (530 + 17)/776=71.4%. Positivity on the HPV DNA screening test is the leading risk factor for cervical cancer development. As a result, the first step in family medicine and KETEM activities is to reduce the frequency of these cancers and the complications related to the disease by increasing information and screening examination applications. © 2019 OMU